Trials / Withdrawn
WithdrawnNCT04371523
Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers
Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE): A Parallel Randomized Controlled Trial
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- St. Joseph's Healthcare Hamilton · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objectives of PROVIDE are to: 1. Determine if prophylactic once weekly hydroxychloroquine reduces the incidence of conversion from SARS-2-CoVnasopharyngeal swab negative to positive 2. To determine if weekly prophylactic hydroxychloroquine reduced the severity of COVID-19 symptoms 3. To determine the safety of taking weekly prophylactic hydroxychloroquine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apo-Hydroxychloroquine | Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total. |
| DRUG | Matched Placebo | Matching Placebo |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2020-07-31
- Completion
- 2020-08-30
- First posted
- 2020-05-01
- Last updated
- 2021-09-27
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04371523. Inclusion in this directory is not an endorsement.